Biological
Empasiprubart clinical trials
Also written ARGX-117.
- studies test it
- 14
- open now
- 8
- in phase 3
- 4
- first study started
- 2020
Keep track of what changes. Save the empasiprubart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses empasiprubart is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPRecruitingPhase 3argenxNCT06920004Written as empasiprubart
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPRecruitingPhase 3argenxNCT07091630Written as Empasiprubart IV
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisRecruitingPhase 2argenxNCT07673627Written as Empasiprubart IV
- A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré SyndromeNot yet recruitingPhase 2argenxNCT07821762Written as Empasiprubart IV
- A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor NeuropathyRecruitingPhase 1argenxNCT07610564Written as Empasiprubart IV
- ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to EfgartigimodRecruitingPhase 2argenxNCT07284420Written as Empasiprubart IV
- A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating PolyradiculoneuropathyNot yet recruitingPhase 2/3argenxNCT07638566Written as Empasiprubart IV
- A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsRecruitingPhase 1argenxNCT07612020Written as empasiprubart IV
- ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionActive, not recruitingPhase 2argenxNCT05907096Written as ARGX-117
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyActive, not recruitingPhase 3argenxNCT06742190Written as Empasiprubart
- A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyCompletedPhase 2argenxNCT05225675Written as ARGX-117
- A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor NeuropathyActive, not recruitingPhase 2argenxNCT05405361Written as ARGX-117
- A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisActive, not recruitingPhase 2argenxNCT06284954Written as Empasiprubart IV
- SAD and MAD Study With IV and SC Doses of ARGX-117CompletedPhase 1argenxNCT04532125Written as ARGX-117
Codes
What other systems call empasiprubart · ClinicalTrials.gg INT017616
- UNII (FDA) PVA73UA67LEMPASIPRUBARTOne source FDA
- NCI Thesaurus C190478EmpasiprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PVA73UA67L | EMPASIPRUBART | One source FDA |
| NCI Thesaurus | C190478 | Empasiprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.